OncLive
@onclive.bsky.social
Healthcare publisher of oncology focused articles, videos, panel discussions, and much more that run the gamut of oncology care and management.
🚨 BREAKING NEWS 🚨: @fda.gov Approves Perioperative Enfortumab Vedotin Plus Pembrolizumab for Cisplatin-Ineligible MIBC
Here's what you should know about the decision: www.onclive.com/view/fda-app...
#oncology #fdanews
Here's what you should know about the decision: www.onclive.com/view/fda-app...
#oncology #fdanews
November 21, 2025 at 5:29 PM
🚨 BREAKING NEWS 🚨: @fda.gov Approves Perioperative Enfortumab Vedotin Plus Pembrolizumab for Cisplatin-Ineligible MIBC
Here's what you should know about the decision: www.onclive.com/view/fda-app...
#oncology #fdanews
Here's what you should know about the decision: www.onclive.com/view/fda-app...
#oncology #fdanews
BREAKING❗: @fda.gov Grants Accelerated Approval to Sevabertinib in HER2-Mutated Nonsquamous NSCLC
Learn more about this regulatory decision below. 👇
🔗https://www.onclive.com/view/fda-grants-accelerated-approval-to-sevabertinib-in-her2-mutated-nonsquamous-nsclc
#lcsm #oncology #FDAapproved
Learn more about this regulatory decision below. 👇
🔗https://www.onclive.com/view/fda-grants-accelerated-approval-to-sevabertinib-in-her2-mutated-nonsquamous-nsclc
#lcsm #oncology #FDAapproved
November 19, 2025 at 8:05 PM
BREAKING❗: @fda.gov Grants Accelerated Approval to Sevabertinib in HER2-Mutated Nonsquamous NSCLC
Learn more about this regulatory decision below. 👇
🔗https://www.onclive.com/view/fda-grants-accelerated-approval-to-sevabertinib-in-her2-mutated-nonsquamous-nsclc
#lcsm #oncology #FDAapproved
Learn more about this regulatory decision below. 👇
🔗https://www.onclive.com/view/fda-grants-accelerated-approval-to-sevabertinib-in-her2-mutated-nonsquamous-nsclc
#lcsm #oncology #FDAapproved
BREAKING NEWS 🚨: @fda.gov Grants Full Approval to Tarlatamab ES-SCLC 🫁
Read more about this decision here 📰: onclive.com/view/fda-gra...
#lcsm #oncology #FDAapproved
Read more about this decision here 📰: onclive.com/view/fda-gra...
#lcsm #oncology #FDAapproved
November 19, 2025 at 7:53 PM
BREAKING NEWS 🚨: @fda.gov Grants Full Approval to Tarlatamab ES-SCLC 🫁
Read more about this decision here 📰: onclive.com/view/fda-gra...
#lcsm #oncology #FDAapproved
Read more about this decision here 📰: onclive.com/view/fda-gra...
#lcsm #oncology #FDAapproved
This episode of OncLive On Air was filmed LIVE at #CFS25! Hear @benlevylungdoc.bsky.social & Dr Tagawa highlight developments in GU cancer management. Watch the video on our site, or listen wherever you get your podcasts! @weillcornell.bsky.social #kcsm #pcsm
www.onclive.com/view/psma-th...
www.onclive.com/view/psma-th...
November 13, 2025 at 9:42 PM
This episode of OncLive On Air was filmed LIVE at #CFS25! Hear @benlevylungdoc.bsky.social & Dr Tagawa highlight developments in GU cancer management. Watch the video on our site, or listen wherever you get your podcasts! @weillcornell.bsky.social #kcsm #pcsm
www.onclive.com/view/psma-th...
www.onclive.com/view/psma-th...
BREAKING: @fda.gov Approves New Pertuzumab Biosimilar for Select HER2+ Breast Cancer Subtypes
Read more: www.onclive.com/view/fda-app...
#FDAapproved #bcsm #oncology
Read more: www.onclive.com/view/fda-app...
#FDAapproved #bcsm #oncology
November 13, 2025 at 7:58 PM
BREAKING: @fda.gov Approves New Pertuzumab Biosimilar for Select HER2+ Breast Cancer Subtypes
Read more: www.onclive.com/view/fda-app...
#FDAapproved #bcsm #oncology
Read more: www.onclive.com/view/fda-app...
#FDAapproved #bcsm #oncology
Sign up to read insights from @surbhisidanamd.bsky.social & Joshua Richter, MD, about how the @fda.gov approval of BVd is set to reframe R/R myeloma management! @stanfordhealthcare.bsky.social @mountsinainyc.bsky.social #mmsm #hematology
www.onclive.com/view/bvd-app...
www.onclive.com/view/bvd-app...
November 7, 2025 at 2:03 PM
Sign up to read insights from @surbhisidanamd.bsky.social & Joshua Richter, MD, about how the @fda.gov approval of BVd is set to reframe R/R myeloma management! @stanfordhealthcare.bsky.social @mountsinainyc.bsky.social #mmsm #hematology
www.onclive.com/view/bvd-app...
www.onclive.com/view/bvd-app...
BREAKING 🚨: @fda.gov Approves Subcutaneous Daratumumab for High-Risk Smoldering Multiple Myeloma
Read all about it 📰: onclive.com/view/fda-app...
#mmsm #FDAapproved #oncology
Read all about it 📰: onclive.com/view/fda-app...
#mmsm #FDAapproved #oncology
November 6, 2025 at 8:12 PM
BREAKING 🚨: @fda.gov Approves Subcutaneous Daratumumab for High-Risk Smoldering Multiple Myeloma
Read all about it 📰: onclive.com/view/fda-app...
#mmsm #FDAapproved #oncology
Read all about it 📰: onclive.com/view/fda-app...
#mmsm #FDAapproved #oncology
See OncLive’s recap of GI cancer data from #ESMO25!
Sign up to hear from Drs Harding and Capdevila about advances in the management of biliary tract cancer, pancreatic cancer, NETs, and more!
@mskcancercenter.bsky.social @vallhebron.com @myesmo.bsky.social #oncology
www.onclive.com/view/esmo-20...
Sign up to hear from Drs Harding and Capdevila about advances in the management of biliary tract cancer, pancreatic cancer, NETs, and more!
@mskcancercenter.bsky.social @vallhebron.com @myesmo.bsky.social #oncology
www.onclive.com/view/esmo-20...
October 31, 2025 at 2:06 PM
See OncLive’s recap of GI cancer data from #ESMO25!
Sign up to hear from Drs Harding and Capdevila about advances in the management of biliary tract cancer, pancreatic cancer, NETs, and more!
@mskcancercenter.bsky.social @vallhebron.com @myesmo.bsky.social #oncology
www.onclive.com/view/esmo-20...
Sign up to hear from Drs Harding and Capdevila about advances in the management of biliary tract cancer, pancreatic cancer, NETs, and more!
@mskcancercenter.bsky.social @vallhebron.com @myesmo.bsky.social #oncology
www.onclive.com/view/esmo-20...
Vicky Makker, MD, Antonio Gonzalez-Martin, MD,
Dana Chase, MD, and Vanda Salutari, MD, highlight some of the top data in gynecologic oncology presented at #ESMO25
Watch and read their exclusive insights! #ovca #gynsm
www.onclive.com/view/emergin...
Dana Chase, MD, and Vanda Salutari, MD, highlight some of the top data in gynecologic oncology presented at #ESMO25
Watch and read their exclusive insights! #ovca #gynsm
www.onclive.com/view/emergin...
October 28, 2025 at 1:38 PM
Vicky Makker, MD, Antonio Gonzalez-Martin, MD,
Dana Chase, MD, and Vanda Salutari, MD, highlight some of the top data in gynecologic oncology presented at #ESMO25
Watch and read their exclusive insights! #ovca #gynsm
www.onclive.com/view/emergin...
Dana Chase, MD, and Vanda Salutari, MD, highlight some of the top data in gynecologic oncology presented at #ESMO25
Watch and read their exclusive insights! #ovca #gynsm
www.onclive.com/view/emergin...
BREAKING 🚨: @fda.gov Approves Revumenib for R/R NMP1-Mutant AML
Learn more here: 🔗 onclive.com/view/fda-app...
#leusm #oncology #FDAapproved
Learn more here: 🔗 onclive.com/view/fda-app...
#leusm #oncology #FDAapproved
October 24, 2025 at 5:33 PM
BREAKING 🚨: @fda.gov Approves Revumenib for R/R NMP1-Mutant AML
Learn more here: 🔗 onclive.com/view/fda-app...
#leusm #oncology #FDAapproved
Learn more here: 🔗 onclive.com/view/fda-app...
#leusm #oncology #FDAapproved
It’s the final day of #ESMO25, but things are far from slowing down! 💥 We’ve got a full schedule of interviews and sessions ahead, so stay tuned for live updates and exclusive insights throughout the day. @myesmo.bsky.social #Oncology
October 20, 2025 at 8:56 AM
It’s the final day of #ESMO25, but things are far from slowing down! 💥 We’ve got a full schedule of interviews and sessions ahead, so stay tuned for live updates and exclusive insights throughout the day. @myesmo.bsky.social #Oncology
We’ve officially hit the halfway point of #ESMO25 here in Berlin! 🇩🇪
Today’s agenda is packed with some of the most anticipated presentations of the meeting — stay tuned for live updates on our interview lineup and a sneak peek at exclusive content coming soon.
@myesmo.bsky.social #Oncology
Today’s agenda is packed with some of the most anticipated presentations of the meeting — stay tuned for live updates on our interview lineup and a sneak peek at exclusive content coming soon.
@myesmo.bsky.social #Oncology
October 19, 2025 at 8:36 AM
We’ve officially hit the halfway point of #ESMO25 here in Berlin! 🇩🇪
Today’s agenda is packed with some of the most anticipated presentations of the meeting — stay tuned for live updates on our interview lineup and a sneak peek at exclusive content coming soon.
@myesmo.bsky.social #Oncology
Today’s agenda is packed with some of the most anticipated presentations of the meeting — stay tuned for live updates on our interview lineup and a sneak peek at exclusive content coming soon.
@myesmo.bsky.social #Oncology
Hallo Berlin! 🇩🇪 We’re diving right into our first full day of live coverage at #ESMO2025! Follow along all weekend for real-time conference updates and expert takes on the latest and greatest advancements in #oncology! @myesmo.bsky.social
October 17, 2025 at 9:58 AM
Hallo Berlin! 🇩🇪 We’re diving right into our first full day of live coverage at #ESMO2025! Follow along all weekend for real-time conference updates and expert takes on the latest and greatest advancements in #oncology! @myesmo.bsky.social
It's time for the #FiveUnder5 🕓, your go-to roundup of the top 5 #oncology videos of the week. @washumedicine.bsky.social @akritigjain.bsky.social @clevelandclinic.bsky.social @cityofhope.bsky.social @harvardmed.bsky.social
Watch the clips: 📽️: www.onclive.com/view/five-un...
#bcsm #mmsm
Watch the clips: 📽️: www.onclive.com/view/five-un...
#bcsm #mmsm
October 13, 2025 at 12:57 AM
It's time for the #FiveUnder5 🕓, your go-to roundup of the top 5 #oncology videos of the week. @washumedicine.bsky.social @akritigjain.bsky.social @clevelandclinic.bsky.social @cityofhope.bsky.social @harvardmed.bsky.social
Watch the clips: 📽️: www.onclive.com/view/five-un...
#bcsm #mmsm
Watch the clips: 📽️: www.onclive.com/view/five-un...
#bcsm #mmsm
It's time for the #OncFive 5⃣, where we bring you the top 5 stories of the week in the world of #oncology.
Learn more about the items on the list: www.onclive.com/view/the-onc...
Learn more about the items on the list: www.onclive.com/view/the-onc...
October 11, 2025 at 7:45 PM
It's time for the #OncFive 5⃣, where we bring you the top 5 stories of the week in the world of #oncology.
Learn more about the items on the list: www.onclive.com/view/the-onc...
Learn more about the items on the list: www.onclive.com/view/the-onc...
GI oncology experts share insights on the most anticipated abstracts upcoming at the #ESMO25 Congress. @mdanderson.bsky.social @mayocliniccancer.bsky.social @clevelandclinic.bsky.social @myesmo.bsky.social #oncology
Sign up to read their full insights! ⬇️
www.onclive.com/view/esmo-20...
Sign up to read their full insights! ⬇️
www.onclive.com/view/esmo-20...
October 9, 2025 at 2:18 PM
GI oncology experts share insights on the most anticipated abstracts upcoming at the #ESMO25 Congress. @mdanderson.bsky.social @mayocliniccancer.bsky.social @clevelandclinic.bsky.social @myesmo.bsky.social #oncology
Sign up to read their full insights! ⬇️
www.onclive.com/view/esmo-20...
Sign up to read their full insights! ⬇️
www.onclive.com/view/esmo-20...
Urothelial Cancer Monthly Rewind: Key News and Expert Insights You May Have Missed in September 2025 #oncology #urothelialcancer #urology
www.onclive.com/view/urothel...
www.onclive.com/view/urothel...
October 8, 2025 at 8:14 PM
Urothelial Cancer Monthly Rewind: Key News and Expert Insights You May Have Missed in September 2025 #oncology #urothelialcancer #urology
www.onclive.com/view/urothel...
www.onclive.com/view/urothel...
BREAKING 🚨: @fda.gov Approves Adjuvant Cemiplimab for Cutaneous Squamous Cell Carcinoma #cscc #oncology
Read more: onclive.com/view/fda-app...
Read more: onclive.com/view/fda-app...
October 8, 2025 at 6:43 PM
BREAKING 🚨: @fda.gov Approves Adjuvant Cemiplimab for Cutaneous Squamous Cell Carcinoma #cscc #oncology
Read more: onclive.com/view/fda-app...
Read more: onclive.com/view/fda-app...
As Q4 begins, the oncology community is closely watching the @fda.gov for several key regulatory decisions.
Sign up 🔐 to access the full list of decisions to watch and what they could mean for clinical practice: www.onclive.com/view/q4-2025...
Sign up 🔐 to access the full list of decisions to watch and what they could mean for clinical practice: www.onclive.com/view/q4-2025...
October 4, 2025 at 2:29 AM
As Q4 begins, the oncology community is closely watching the @fda.gov for several key regulatory decisions.
Sign up 🔐 to access the full list of decisions to watch and what they could mean for clinical practice: www.onclive.com/view/q4-2025...
Sign up 🔐 to access the full list of decisions to watch and what they could mean for clinical practice: www.onclive.com/view/q4-2025...
It's here! Your guide to all the oncologic therapeutic options that were greenlit ✅ by the @fda.gov in September 2025.
Check out the full resource: www.onclive.com/view/onclive...
Check out the full resource: www.onclive.com/view/onclive...
October 3, 2025 at 3:12 PM
It's here! Your guide to all the oncologic therapeutic options that were greenlit ✅ by the @fda.gov in September 2025.
Check out the full resource: www.onclive.com/view/onclive...
Check out the full resource: www.onclive.com/view/onclive...
🚨BREAKING: @fda.gov Approves Lurbinectedin Plus Atezolizumab as First-Line Maintenance Therapy for ES-SCLC #lcsm www.onclive.com/view/fda-app...
October 2, 2025 at 7:38 PM
🚨BREAKING: @fda.gov Approves Lurbinectedin Plus Atezolizumab as First-Line Maintenance Therapy for ES-SCLC #lcsm www.onclive.com/view/fda-app...
With #ESMO25 right around the corner, sign up below to read our exclusive preview featuring expert insights on the most exciting lung cancer abstracts being presented at the meeting!
👉 Sign up and read the full preview: www.onclive.com/view/inside-...
#lungcancer #lcsm #oncology
👉 Sign up and read the full preview: www.onclive.com/view/inside-...
#lungcancer #lcsm #oncology
October 2, 2025 at 3:57 PM
With #ESMO25 right around the corner, sign up below to read our exclusive preview featuring expert insights on the most exciting lung cancer abstracts being presented at the meeting!
👉 Sign up and read the full preview: www.onclive.com/view/inside-...
#lungcancer #lcsm #oncology
👉 Sign up and read the full preview: www.onclive.com/view/inside-...
#lungcancer #lcsm #oncology
As #ESMO25 inches closer, check out the hematologic oncology abstracts that will be featured in oral presentations at this year's meeting.
#lymsm #leusm #oncology www.onclive.com/view/hematol...
#lymsm #leusm #oncology www.onclive.com/view/hematol...
September 30, 2025 at 2:15 PM
As #ESMO25 inches closer, check out the hematologic oncology abstracts that will be featured in oral presentations at this year's meeting.
#lymsm #leusm #oncology www.onclive.com/view/hematol...
#lymsm #leusm #oncology www.onclive.com/view/hematol...
🌟 It's time for the #OncFive 5️⃣ 🌟 Learn more about the top 5 #oncology stories from this week: onclive.com/view/the-onc... #bcsm #mmsm
September 28, 2025 at 4:20 PM
🌟 It's time for the #OncFive 5️⃣ 🌟 Learn more about the top 5 #oncology stories from this week: onclive.com/view/the-onc... #bcsm #mmsm
It's time for the #FiveUnder5 🕒. Check out the top #oncology videos of the week: www.onclive.com/view/five-un...
@danafarber.bsky.social @harvardmed.bsky.social @mountsinainyc.bsky.social #bcsm #pancsm #mmsm #medtwitter
@danafarber.bsky.social @harvardmed.bsky.social @mountsinainyc.bsky.social #bcsm #pancsm #mmsm #medtwitter
September 28, 2025 at 4:16 PM
It's time for the #FiveUnder5 🕒. Check out the top #oncology videos of the week: www.onclive.com/view/five-un...
@danafarber.bsky.social @harvardmed.bsky.social @mountsinainyc.bsky.social #bcsm #pancsm #mmsm #medtwitter
@danafarber.bsky.social @harvardmed.bsky.social @mountsinainyc.bsky.social #bcsm #pancsm #mmsm #medtwitter